Literature DB >> 18652586

Clear differences in adiponectin level and glutathione redox status revealed in obese and normal-weight patients with psoriasis.

S Kaur1, K Zilmer, C Kairane, M Kals, M Zilmer.   

Abstract

BACKGROUND: Several studies have shown increased prevalence of obesity in patients with psoriasis.
OBJECTIVES: To characterize both inflammatory- and oxidative stress-related differences between obese patients with psoriasis (OPP) and normal-weight patients with psoriasis (NWPP).
METHODS: The plasma concentrations of adiponectin and interleukin (IL)-6 were analysed by quantitative sandwich enzyme immunoassay technique in 10 patients with a body mass index (BMI)<25 and 12 patients with a BMI>30. Total glutathione and oxidized glutathione levels were measured spectrophotometrically.
RESULTS: Plasma concentration of adiponectin in NWPP was more than twice the level in healthy normal-weight controls (P<0.001), while such an elevation did not occur in OPP. OPP were characterized by a significantly increased IL-6 level, which correlated negatively with the adiponectin level (r=-0.85, P<0.001). The glutathione redox status, which was also inversely correlated with the adiponectin level (r=-0.63, P<0.05), was associated with significantly increased oxidative stress in the OPP compared with the NWPP or controls.
CONCLUSIONS: Obesity in patients with psoriasis is associated with both decreased plasma levels of protective adiponectin compared with NWPP, and enhanced systemic inflammation and oxidative stress. These findings are in concordance with high prevalence of diseases related to lower adiponectin levels among psoriasis patients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18652586     DOI: 10.1111/j.1365-2133.2008.08759.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  22 in total

Review 1.  Body composition in gene knockouts of sulfur amino acid-metabolizing enzymes.

Authors:  Amany K Elshorbagy
Journal:  Mamm Genome       Date:  2014-06-21       Impact factor: 2.957

Review 2.  Non-alcoholic fatty liver disease and psoriasis: So far, so near.

Authors:  Giulia Ganzetti; Anna Campanati; Annamaria Offidani
Journal:  World J Hepatol       Date:  2015-03-27

3.  Psoriasis Improvement in Patients Using Glutathione-enhancing, Nondenatured Whey Protein Isolate: A Pilot Study.

Authors:  Ronald Prussick; Lisa Prussick; Jimmy Gutman
Journal:  J Clin Aesthet Dermatol       Date:  2013-10

Review 4.  Cysteine/cystine redox signaling in cardiovascular disease.

Authors:  Young-Mi Go; Dean P Jones
Journal:  Free Radic Biol Med       Date:  2010-12-03       Impact factor: 7.376

Review 5.  Psoriasis and vascular disease-risk factors and outcomes: a systematic review of the literature.

Authors:  Rita V Patel; Michael L Shelling; Srdjan Prodanovich; Daniel G Federman; Robert S Kirsner
Journal:  J Gen Intern Med       Date:  2011-04-07       Impact factor: 5.128

Review 6.  Biological products for the treatment of psoriasis: therapeutic targets, pharmacodynamics and disease-drug-drug interaction implications.

Authors:  Jie Wang; Yow-Ming C Wang; Hae-Young Ahn
Journal:  AAPS J       Date:  2014-07-04       Impact factor: 4.009

Review 7.  Psoriasis.

Authors:  Paola Di Meglio; Federica Villanova; Frank O Nestle
Journal:  Cold Spring Harb Perspect Med       Date:  2014-08-01       Impact factor: 6.915

8.  Obesity and risk of incident psoriatic arthritis in US women.

Authors:  Wenqing Li; Jiali Han; Abrar A Qureshi
Journal:  Ann Rheum Dis       Date:  2012-05-05       Impact factor: 19.103

9.  Beta-mecaptoethanol suppresses inflammation and induces adipogenic differentiation in 3T3-F442A murine preadipocytes.

Authors:  Wen Guo; Yahui Li; Wentao Liang; Siu Wong; Caroline Apovian; James L Kirkland; Barbara E Corkey
Journal:  PLoS One       Date:  2012-07-23       Impact factor: 3.240

10.  Chronic skin-specific inflammation promotes vascular inflammation and thrombosis.

Authors:  Yunmei Wang; Huiyun Gao; Candace M Loyd; Wen Fu; Doina Diaconu; Shijian Liu; Kevin D Cooper; Thomas S McCormick; Daniel I Simon; Nicole L Ward
Journal:  J Invest Dermatol       Date:  2012-05-10       Impact factor: 8.551

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.